Understanding a potentially new therapeutic target in incurable childhood acute lymphoblastic leukaemia
Dissecting the role of CD133/PROM1 in MLL rearranged acute lymphoblastic leukaemia to develop novel targeted therapy
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Dissecting the role of CD133/PROM1 in MLL rearranged acute lymphoblastic leukaemia to develop novel targeted therapy
The Role of Cut-and-Run, an Aberrant V(D)J Recombination Reaction, in the Development of Acute Lymphoblastic Leukaemias with Poor Prognosis
Towards a new therapy against childhood brain cancer: How does the Zika virus kill aggressive brain tumour cells?
Investigating repurposed drugs to decrease the progression of Ewing’s sarcoma
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study
Dissecting the role of MYCN in neuroblastoma initiation
Drug repurposing targeting immunomodulatory Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis
Identifying whether children with ALCL, ALK- also harbour other genetic changes in their tumours, and what affect this has on how their cancer progresses. This knowledge can help to guide clinicians about how best to treat children with this rarer sub-form of lymphoma.
Exploring whether a new approach to identifying ependymoma tumours can help support better, more tailored, and potentially less invasive treatment for children with this type of cancer.